Azelastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H24ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZQI909440X, chemically known as 1(2h)-phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)- but generally known as azelastine, which bears US NIH Compound Identifier 2267. Azelastine most often comes in base and hydrochloride forms. European Medicines Agency schedules Azelastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05649MIG. The term AZELASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, No10, 1977, List 17). World Health Organization schedules azelastine in its Anatomical Therapeutic Chemical (ATC) Classification. AZELASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule azelastine under HS 29339930 and SITC 51577. As of Q4 2014, AZELASTINE remains the US FDA Preferred Term for this commodity. Azelastine bears US NLM identifiers UMLS ID C0052762 and NCI Concept Code C61643. SMILES: CLC1CCC(CC2NN(C3CCCN(CC3)C)C(=O)C3C2CCCC3)CC1.